updated 1/26/2011 11:47:15 AM ET 2011-01-26T16:47:15

VENICE, Fla., Jan. 26, 2011 (GLOBE NEWSWIRE) -- SinoFresh® HealthCare, Inc., (Pink Sheets:SFSH) is pleased to announce it has launched a program to initiate studies providing additional data to evaluate the efficacy of SinoFresh Homeopathic Antiseptic Nasal Spray in reducing the onset and duration of a number of common illnesses such as sinusitis, common colds and flu. SinoFresh HealthCare, Inc. anticipates that the initial study designed to evaluate symptom relief for chronic sinusitis sufferers, estimated to be as many as 37 million Americans, will commence by the end of the Q2 2011.

William Wilferth, Chief Pharmacist and Vice President of R&D states, "With our recent acquisition of SRS International, SinoFresh is now in a position to initiate a program to fully evaluate the impact of the product's use for a number of common illnesses such as sinusitis, common colds and flu. SRS has extensive expertise in the design, conduct and evaluation of products like SinoFresh's Nasal Spray and will be able to develop the data necessary for the company to inform users of the full benefits of SinoFresh Nasal Spray use. We look forward to the initiation of this program and the exciting potential it holds for new and expanded uses of our premier product."

Wilferth continues, "We have been encouraged to take this next important step by our nearly 10 years of input from both consumers as well as the medical community citing strong anecdotal evidence that the SinoFresh Homeopathic Antiseptic Nasal Spray has brought significant relief to sinusitis sufferers. Numerous regular users of the product have also reported to us a significant reduction in the incidents of cold and flu infections. While we cannot make these claims now, we have reason to be optimistic in evaluating the regular use of a nasal antiseptic in reducing the onset and duration of upper respiratory contracted illnesses."

"We are excited about initiating this program to support and build the research and clinical database on our patented lead product," stated David R. Olund, CEO. "We believe that success in these clinical initiatives has the potential to expand product usage, open additional markets and dramatically impact long term shareholder value."

SinoFresh HealthCare, Inc. is a publicly traded company (Pink Sheets:SFSH) based in Venice, Florida, that manufactures and distributes nasal, oral and topical antiseptic germ-killing products. SinoFresh products are marketed and distributed globally through a network of strategic wholesale and retail partners. SinoFresh Healthcare, Inc's, premier product, SinoFresh Antiseptic Homeopathic Nasal spray has in laboratory tests shown effective antiseptic capability against a variety of pathogens such as MRSA, E-Coli, H1N1 and a broad range of other viruses, molds, fungi and bacteria. 

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Our forward-looking statements express our current expectations or forecasts of possible future results or events, including projections of future performance, statements of management's plans and objectives, future contracts, and forecasts of trends and other matters. Forward-looking statements speak only as of the date of this filing, and we undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur. You can identify these statements by the fact that they do not relate strictly to historic or current facts and often use words such as "anticipate", "estimate", "expect", "believe", "will likely result", "outlook", "project" and other words and expressions of similar meaning. No assurance can be given that the results in any forward-looking statements will be achieved and actual results could be affected by one or more factors, which could cause them to differ materially. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act.

CONTACT: SinoFresh HealthCare Inc.
         Investor Relations
         941.375.8174 option 8

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com